Tecnología para depurar agua basada en la madera
En este Short os hablamos de una nueva metodología de purificación del agua que utiliza derivados de la madera. …
Tecnología para depurar agua basada en la madera Read More »
Uncategorized
Desechos agrícolas como posibles fuentes de compuestos bioactivos
El uso de residuos agrícolas para la obtención de compuestos polifenólicos es de gran interés científico, ya que tales residuos son considerados un recurso abundante, biorrenovable y de bajo costo. Numerosos compuestos polifenólicos derivados de residuos agr …
Desechos agrícolas como posibles fuentes de compuestos bioactivos Read More »
Controlando la actividad neuronal con fotones como neurotransmisores
Nuestro cerebro está formado por miles de millones de neuronas que están conectadas entre sí formando redes complejas. Estas neuronas se comunican mediante un proceso llamado transmisión sináptica, en el cual se envían señales eléctricas, poten …
Controlando la actividad neuronal con fotones como neurotransmisores Read More »
Nanopartículas para prevenir y tratar alergias
La alergia a los cacahuetes es una de las más comunes. Según algunas estimaciones, afecta a 1 de cada 50 niños, y los casos más graves conducen a una reacción inmunitaria potencialmente mortal llamada shock anafiláctico. Actualmente, solo existe un …
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program
Sirnaomics Ltd., a leading biopharmaceutical company in discovery and development of RNAi therapeutics, announced the launch of a Phase I clinical trial of STP122G based on the Group’s GalNAc Factor XI Program.
Sirnaomics Launches Phase I Clinical Trial for GalNAc Factor XI Program Read More »
CANbridge Pharmaceuticals Spinal Muscular Atrophy Gene Therapy Abstract Accepted for Presentation at the American Society for Gene and Cell Therapy annual Meeting
CANbridge Pharmaceuticals, Inc. announced that the American Society for Gene and Cell Therapy has accepted the following abstract for presentation at the ASCGT Annual Meeting, May 16-20, in Los Angeles, CA.
Initiation of New Patients on Evobrutinib Paused in the U.S.; Fully Enrolled Phase III Evobrutinib Studies Continue
Merck KGaA, Darmstadt, Germany, a leading science and technology company, announced the U.S. Food and Drug Administration has placed a partial clinical hold on the initiation of new patients on evobrutinib and patients with less than 70 days exposure to study medication in the U.S.
HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023
HUTCHMED Limited announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the American Association for Cancer Research Annual Meeting 2023, which will take place from April 14 to 19, 2023 in Orlando, Florida.
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares
InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at an offering price of $4.25 per ordinary share.
InflaRx Announces Pricing of $40 Million Public Offering of Ordinary Shares Read More »
GC Genome-KAIST team Announces Publication of a Groundbreaking AI-Based Liquid Biopsy Technology for Multi-Cancer Early Detection and Localization in Nature Communications
GC Genome Corporation, a leading genomic diagnostics company, announced the publication of a new study in Nature Communications, showcasing the company’s novel AI-based liquid biopsy technology.